NeuroX1 🧬

Traditional drug discovery methods are slow, expensive, and have high failure rates.

This week’s company leverages AI to identify targets of neurological diseases and generate drug candidates.

Drivers: The platform analyzes biological data to uncover underlying causes behind brain diseases.

Discovery: NeuroX1 designs computational compounds, potentially speeding up the time consuming process of drug discovery.

Industry: Biotech

Headquarters: Austin, TX

Year founded: 2021

Employee count: 10

Investors: Drive Capital, Trousdale Partners, Vibe Capital, Syntax Ventures, Next Sequence VC, Techstars

Amount raised: $2.12 million

Currently raising: $2 million Seed extension

Business model: B2B; Upfront payment for early discovery and then progressively increasing milestones as drug assets progress through each phase of clinical development, plus a royalty if approved.  

Early traction: 3 industry co-development partnerships and 2 academic collaborations.

Crafting your startup’s cash management strategy? 

First, divide your funds into three categories: liquid, short-term, and strategic. 

From there, it’s about optimizing for risk and yield according to those time horizons. 

But how much should you put in each category?

Market Opportunity: The neurological disorder drugs market is expected to grow nearly 5% annually due to the rising prevalence of diseases among aging populations and demand for treatments.

Drug Discovery: NeuroX1's use of generative chemistry dramatically shortens the time and reduces the cost needed to find new drugs, representing a major leap forward in medicine development.

Innovative Business Model: The company’s B2B model, which combines upfront payments with milestones and royalties, aligns incentives across the drug development process while fostering innovation.

AI Hallucinations: Like other advanced algorithms, NeuroX1’s platform might generate chemically valid but biologically unproven structures, potentially leading to redirected research paths and careful client expectation management.

Non-Recurring Revenue: While NeuroX1 has an innovative monetization model, its dependence on performance could delay unrealized annualized revenue.

Algorithm Overlap: If NeuroX1's AI learns and adapts from multiple lab projects simultaneously, there's a risk that one project's discovery process could inadvertently influence another's, diluting the exclusive value of expensive, proprietary research for organizations.

/

Max Dordevic, CEO: Former CEO of Veritas Innovation and life science researcher.

Lucas Myers, CTO: Software engineer with a background in applied math, healthcare data pipelines, infrastructure, and product management.

Conner Myers, PhD, CIO: Physicist and high-performance computing expert, specialized in GPU acceleration of physics simulations at Lawrence Livermore and Sandia National Labs.

Cradle: Backed by Kindred Capital, Index Ventures, and others.

CHARM Therapeutics: Backed by NVentures, General Catalyst, Khosla Ventures, F-Prime Capital, and others.

Aquemia: Backed by Wendel Growth, Bpifrance, Eurazeo, and others.

Pangea Botanica: Backed by No Label Ventures, Seaside Ventures, Kadmos Kapital, and others.

Thanks to all of you who came out to our event last night. More to come…

The results are in: Blockpliance, a platform that arms institutions against illicit blockchain transactions, was favored in last week’s poll.

Subscriber feedback: “Blockpliance gives the power back to financial institutions to ensure the security of virtual transactions — It’s a no-brainer.”